Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

WAYS & MEANS/HEALTH SUBCOMMITTEE MEMBER RUSSO’s

Executive Summary

WAYS & MEANS/HEALTH SUBCOMMITTEE MEMBER RUSSO's (D-Ill.) top priority will be legislation to establish a national health care system. Russo's move to the House subcommittee was approved by committee Democrats during a Dec. 5 organizational meeting. Russo is a former member of the health panel but gave up the slot when he joined the House Budget Committee in 1984. Russo is leaving the budget panel this year and is entitled to reclaim his health subcommittee position. Russo has been working on national health insurance legislation for more than a year and hopes to introduce it early in the session, aides said. He was a prime sponsor of legislation enacted in 1989 to repeal the Medicare Catastrophic Care Act. At that time, he advised colleagues to "vote for the [repeal] amendment and begin today the debate to establish a universal health care system that delivers the best quality health care to all citizens at an affordable price" ("The Pink Sheet" Oct. 9, p. 15). During a stint on the Energy & Commerce Committee, however, he voted against the Carter Administration's hospital cost control proposals. First elected to Congress in 1974, Russo represents Illinois' third district, encompassing the southwestern portion of Chicago and suburbs. The Chicago native is seen as a close ally of fellow Chicagoan Rep. Rostenkowski (D-Ill.), chairman of the Ways & Means panel. Russo also has worked his way up through the House leadership to his present post as a deputy majority whip. Russo replaces Rep. Pickle (D-Tex.) who had been one of the subcommittee's more conservative members and an advocate of rural concerns. In other changes considered by Democratic and Republican caucuses Dec. 5, the full Ways and Means Committee will add three new members: Democratic Rep. McDermott (Wash.) and Republican Reps. Bunning (Ky.) and Grandy (Iowa). The Republican members were recommended by their party's Committee on Committees, and must be ratified by the Republican Conference in January. McDermott, a psychiatrist, is expected to be active on health care issues. The House Appropriations Committee added four new Democrats to its ranks: Pelosi (Calif.), Price (N.C.), Skaggs (Colo.) and Smith (Fla.). Its new Republican member is Vucanovich (Nev.). The appointments reflect an increase in the number of Democrats to Republicans on the Appropriations Committee. The current ratio is 35/22. It will change to 37/22. The Republican Committee on Committees also recommended that Reps. Hastert (Ill.) and Holloway (La.) be appointed to the Energy and Commerce Committee. This may reflect a decrease in the final number of Republican members on the committee since three Republicans seats were available, but only two members were selected. Selections have not been named for the three Democratic seats open on the committee.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

UsernamePublicRestriction

Register

PS142970

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel